Back to Search Start Over

Diabetes and hypertension: Pivotal involvement of purinergic signaling

Authors :
Vera Maria Morsch
Karine Paula Reichert
Milagros Fanny Vera Castro
Naiara Stefanello
Vanessa Valéria Miron
Andréia Machado Cardoso
Maria Rosa Chitolina Schetinger
Charles Elias Assmann
Nathieli B. Bottari
Source :
Biomedicine & Pharmacotherapy, Vol 137, Iss, Pp 111273-(2021), Biomedicine & Pharmacotherapy
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Graphical abstract<br />Highlights • The coexistence of diabetes and hypertension represents a major risk factor for the onset of cardiovascular problems. • The purinergic signaling pathway constitutes a ubiquitous system of cell–cell communication. • Purinergic system plays a pivotal role in physiopathological conditions. • Several alterations in purine metabolism have been demonstrated in diabetes and hypertension. • Purinergic system can be an important target related to therapeutic approaches in diabetes and hypertension.<br />Diabetes mellitus (DM) and hypertension are highly prevalent worldwide health problems and frequently associated with severe clinical complications, such as diabetic cardiomyopathy, nephropathy, retinopathy, neuropathy, stroke, and cardiac arrhythmia, among others. Despite all existing research results and reasonable speculations, knowledge about the role of purinergic system in individuals with DM and hypertension remains restricted. Purinergic signaling accounts for a complex network of receptors and extracellular enzymes responsible for the recognition and degradation of extracellular nucleotides and adenosine. The main components of this system that will be presented in this review are: P1 and P2 receptors and the enzymatic cascade composed by CD39 (NTPDase; with ATP and ADP as a substrate), CD73 (5′-nucleotidase; with AMP as a substrate), and adenosine deaminase (ADA; with adenosine as a substrate). The purinergic system has recently emerged as a central player in several physiopathological conditions, particularly those linked to inflammatory responses such as diabetes and hypertension. Therefore, the present review focuses on changes in both purinergic P1 and P2 receptor expression as well as the activities of CD39, CD73, and ADA in diabetes and hypertension conditions. It can be postulated that the manipulation of the purinergic axis at different levels can prevent or exacerbate the insurgency and evolution of diabetes and hypertension working as a compensatory mechanism.

Subjects

Subjects :
BP, blood pressure
HIF-1α, hypoxia-inducible factor-1α
Adenosine
Up4A, uridine adenosine tetraphosphate
Cell Communication
Review
APCs, antigen presenting cells
BFR, blood flow restriction
0302 clinical medicine
PNP, purine nucleoside phosphorylase
Diabetic cardiomyopathy
Purinergic P2 Receptor Antagonists
HIAE, high intensity aerobic
Medicine
NOS, nitric oxide synthase
5'-Nucleotidase
5′-NT
CD73, ecto-5′-nucleotidase
Ectonucleotidases
GLP-1, glucagon-like peptide-1
General Medicine
PAP, prostatic acid phosphatase
GLUT, glucose transporter
NTPDase1/CD39, E-NTPDase family
030220 oncology & carcinogenesis
TReg, regulatory T cells
ATP, adenosine 5′-triphosphate
P1, purinergic receptors family 1
DBP, diastolic blood pressure
RM1-950
ADP, adenosine 5′-diphosphate
STZ, streptozotocin
LIAE, low intensity aerobic exercise
HIIT, high-intensity intermittent training
03 medical and health sciences
Antigens, CD
Diabetes Mellitus
Humans
Exercise
Ado, Adenosine
PBMCs, peripheral blood mononuclear cells
Pharmacology
NO, nitric oxide
Receptors, Purinergic P2
UTP, uridine-5′-triphosphate
Receptors, Purinergic P1
T2DM, type 2 diabetes mellitus
medicine.disease
IL, interleukin
CGA, chlorogenic acid
030104 developmental biology
Glucose
ER, endoplasmatic reticulum
GABA, gamma-aminobutyric acid
Ino, inosine
PKA, protein kinase A
SHR, spontaneously hypertensive rat
0301 basic medicine
Adenosine Deaminase
STAT3, signal transducer and activator of transcription 3
SIT, sprint interval training
UDP, uridine diphosphate
Bioinformatics
Adenosine deaminase
VO2máx, maximal oxygen uptake
DM, diabetes mellitus
E-NPP, ecto-nucleotide pyrophosphatase/phosphodiesterase
Receptor
ADA, adenosine deaminase
NOD-mice, Non-obese diabetic mice
NF-κB, nuclear factor kappa B
TNF-α, tumor necrosis factor α
biology
AMP, adenosine 5′-monophosphate
Apyrase
T1DM, type 1 diabetes mellitus
Purinergic receptor
E-NTPDase, ecto-nucleoside triphosphate diphosphohydrolase
eNOS, endothelial nitric oxide synthase
MICT, moderate intensity continuous training
Purinergic signalling
IRS-1, insulin receptor substrate 1
VEGF, vascular endothelial growth factor
mRNA, messenger RNA
MSNA, muscle sympathetic nerve activity
Hypertension
Ap3A, diadenosine triphosphate
Blood pressure
Diet, Healthy
DCs, dendritic cells
Purinergic receptors
Signal Transduction
medicine.drug
P2Y, purinergic metabotropic receptor family 2
TNAP, tissue-nonspecific alkaline phosphatase
HbA1c, glycosylated hemoglobin
P2 receptor
CNS, central nervous system
APs, alkaline phosphatases
SIRT1, Sirtuin 1
GPCRs, G-protein-coupled receptors
L-NAME, L-NG-nitroarginine methyl ester
P2X, purinergic ionotropic receptor family 2
Diabetes mellitus
Animals
TXA2, thromboxane A2
ComputingMethodologies_COMPUTERGRAPHICS
NLRP3, NLR family pyrin domain containing 3
cAMP, cyclic adenosine 5′-monophosphate
business.industry
SBP, systolic blood pressure
AngII, angiotensin-II
ATP
AMPK, AMP-activated protein kinase
NFAT, nuclear factor of activated T-cells
Purinergic P1 Receptor Antagonists
DAMP, molecular pattern associated with damage
Purines
TGF-β1, transforming growth factor-beta 1
biology.protein
Therapeutics. Pharmacology
business
DAG, diacylglycerol

Details

Language :
English
ISSN :
07533322
Volume :
137
Database :
OpenAIRE
Journal :
Biomedicine & Pharmacotherapy
Accession number :
edsair.doi.dedup.....34db00a41121e428fb7b9d4795d39e99